Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Patients with pancreatic cystic tumors were divided into control, mucinous tumor and non-mucinous tumor groups, and cfDNA molecules and protein molecules that were significantly altered between different groups were found by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic detection techniques. Multi-omics analysis was performed to construct a more efficient molecular diagnostic marker model. Correlating models with pathological features to find molecular features associated with the degree of malignancy.

Inclusion criteria

• Subjects are ≥ 18 years old, regardless of gender;
• Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;
• Subjects voluntarily accepted radical resection of pancreatic cystic tumors;
• Subjects or family members voluntarily sign the informed consent form for clinical research.

Exclusion criteria

• The excised sample does not contain cystic components, or the cystic fluid cannot be collected;
• Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation;
• Receive antibiotic treatment within 1 week before operation;
• Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor;
• The subjects or their families refused to sign the informed consent form for clinical research.